Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Long-Term Debt Repayments (2016 - 2019)

Altimmune (ALT) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $105062.0 as the latest value for Q4 2019.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $105062.0 in Q4 2019 year-over-year; TTM through Dec 2020 was $135857.0, a 0.0% change, with the full-year FY2020 number at $632000.0, up 116.44% from a year prior.
  • Long-Term Debt Repayments was $105062.0 for Q4 2019 at Altimmune, up from $30795.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $105062.0 in Q4 2019 to a low of -$250009.0 in Q3 2015.
  • A 4-year average of -$64639.6 and a median of $8017.0 in 2016 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: fell 0.0% in 2015, then skyrocketed 15995.96% in 2017.
  • Altimmune's Long-Term Debt Repayments stood at -$250009.0 in 2015, then soared by 132.4% to $80999.0 in 2016, then plummeted by 80.33% to $15935.0 in 2017, then skyrocketed by 559.32% to $105062.0 in 2019.
  • Per Business Quant, the three most recent readings for ALT's Long-Term Debt Repayments are $105062.0 (Q4 2019), $30795.0 (Q3 2019), and $15935.0 (Q2 2017).